What is Intelligent Bio Solutions Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Intelligent Bio Solutions's Probability of Financial Distress (%) is 91.25%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Intelligent Bio Solutions's Probability of Financial Distress (%)
For the Medical Devices subindustry, Intelligent Bio Solutions's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intelligent Bio Solutions's Probability of Financial Distress (%) Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Intelligent Bio Solutions's Probability of Financial Distress (%) falls into.
Intelligent Bio Solutions Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | 2.34 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 91.25% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description
Traded in Other Exchanges
Address
57th Street, 142 West, 11th Floor, New York, NY, USA, 10019
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.
Executives
| Harry Simeonidis |
director, officer: CEO, President |
708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017 |
| Foundation Ma-ran |
10 percent owner |
1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329 |
| Gary W. Rollins Foundation |
10 percent owner |
1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329 |
| David A Jenkins |
director |
P.O. BOX 682838, PARK CITY UT 84068 |
| Jason Isenberg |
director |
1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329 |
| Spiro Kevin Sakiris |
officer: Chief Financial Officer |
708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017 |
| Life Science Biosensor Diagnostics Pty Ltd |
10 percent owner |
LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000 |
| Tom Parmakellis |
director |
708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017 |
| Victoria Gavrilenko |
director |
708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017 |
| Christopher Towers |
director |
1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042 |
| Lawrence B Fisher |
director |
C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017 |
| Leonard Victor Kempler |
director |
708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017 |
| George Margelis |
director |
708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017 |
| Boyages Steven Constantine |
director |
708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017 |
| Jonathan Scott Hurd |
director |
708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017 |
Intelligent Bio Solutions (Intelligent Bio Solutions) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBS has been successfully added to your